Brief: AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel

Kalaris Therapeutics

22/12/2023 12:20

Dec 22 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR PROVIDES UPDATES ON PHASE 3 CLINICAL DEVELOPMENT
PROGRAM
FOR POSOLEUCEL, AN ALLOGENEIC VIRUS-SPECIFIC T CELL THERAPY
    * ALLOVIR INC: TO DISCONTINUE ITS THREE PHASE 3 POSOLEUCEL
STUDIES
    * ALLOVIR INC: TO PRIORITIZE CAPITAL PRESERVATION AND REVIEW
STRATEGIC OPTIONS
    * ALLOVIR INC: ALTERNATIVES MAY INCLUDE A MERGER, SALE,
DIVESTITURE OF ASSETS, LICENSING, OR OTHER STRATEGIC TRANSACTION
    * ALLOVIR INC:  PHASE 3 POSOLEUCEL STUDIES WERE UNLIKELY TO
MEET
THEIR PRIMARY ENDPOINTS; NO SAFETY CONCERNS IDENTIFIED
    * ALLOVIR INC: WILL DISCONTINUE PREVENTION, VHC AND ADV
PHASE 3
TRIALS
    * ALLOVIR INC:  AS OF SEPTEMBER 30, 2023, HAD CASH, CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $213.3 MILLION

Source text for Eikon:  ID:nGNX5xtQ4r 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com;))